|
| related topics |
| {product, candidate, development} |
| {property, intellectual, protect} |
| {personnel, key, retain} |
| {cost, contract, operation} |
| {regulation, government, change} |
|
|
If we fail to obtain the capital necessary to fund our operations, we will have to delay, reduce or eliminate our research and development programs or commercialization efforts.
Our stock price could decline significantly based on the results and timing of clinical trials of, and decisions affecting, our product candidates.
Even if we successfully complete clinical trials for Proellex and Androxal, there are no assurances that we will be able to submit, or obtain FDA approval of, a new drug application.
The results of preclinical studies and completed clinical trials are not necessarily predictive of future results, and our current drug candidates may not have favorable results in later studies or trials.
We currently rely on third-party manufacturers and other third parties for production of our product candidates, and our dependence on these manufacturers may impair the development of our product candidates.
We may experience delays in the development of our product candidates if the third-party manufacturers of our product candidates cannot meet FDA requirements relating to Good Manufacturing Practices.
We are thinly staffed and highly dependent on a limited number of management persons and key personnel, and if we lose these members of our team or are unable to attract and retain additional qualified personnel, our future growth and ability to compete would suffer.
Healthcare reform measures could adversely affect our business.
We cannot assure that our manufacture, use or sale of our product candidates will not infringe on the patent rights of others.
We face substantial uncertainty in our ability to protect our patents and proprietary technology.
Risks Relating to our Securities
Full 10-K form ▸
|
|
| related documents |
| 1020214--2/27/2006--CERUS_CORP |
| 1333248--3/16/2009--CADENCE_PHARMACEUTICALS_INC |
| 908259--3/14/2007--OXIGENE_INC |
| 908259--3/14/2008--OXIGENE_INC |
| 1110803--3/6/2006--ILLUMINA_INC |
| 1063665--9/23/2010--CORGENIX_MEDICAL_CORP/CO |
| 1001233--3/1/2007--SANGAMO_BIOSCIENCES_INC |
| 1013238--3/31/2006--ARADIGM_CORP |
| 1028358--3/31/2008--GENITOPE_CORP |
| 874443--3/31/2006--GENELABS_TECHNOLOGIES_INC_/CA |
| 1010086--3/13/2008--SIGA_TECHNOLOGIES_INC |
| 873303--3/16/2007--AVI_BIOPHARMA_INC |
| 873303--3/16/2006--AVI_BIOPHARMA_INC |
| 1001233--3/16/2006--SANGAMO_BIOSCIENCES_INC |
| 1062822--3/12/2007--LEXICON_GENETICS_INC/TX |
| 858803--12/18/2006--AVANIR_PHARMACEUTICALS |
| 907562--3/3/2006--DYAX_CORP |
| 817785--4/4/2007--IMMUNE_RESPONSE_CORP |
| 310158--2/28/2007--SCHERING_PLOUGH_CORP |
| 708717--10/15/2007--ALFACELL_CORP |
| 1038133--3/30/2007--HESKA_CORP |
| 1038133--3/31/2006--HESKA_CORP |
| 907562--3/13/2007--DYAX_CORP |
| 908259--3/14/2006--OXIGENE_INC |
| 1017491--3/12/2008--NEXMED_INC |
| 1023024--3/17/2008--BIOSANTE_PHARMACEUTICALS_INC |
| 1038133--3/16/2009--HESKA_CORP |
| 1038133--3/3/2008--HESKA_CORP |
| 908259--3/16/2010--OXIGENE_INC |
| 1038133--2/22/2010--HESKA_CORP |
|